| 2.28 0.02 (0.89%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.28 | 1-year : | 3.88 |
| Resists | First : | 2.81 | Second : | 3.32 |
| Pivot price | 2.31  |
|||
| Supports | First : | 1.99 | Second : | 1.65 |
| MAs | MA(5) : | 2.27 |
MA(20) : | 2.27 |
| MA(100) : | 2.27 |
MA(250) : | 2.78 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 19.7 |
D(3) : | 20.3 |
| RSI | RSI(14): 48.4 |
|||
| 52-week | High : | 8.81 | Low : | 1.16 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ACXP ] has closed above bottom band by 43.4%. Bollinger Bands are 8.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.4 - 2.42 | 2.42 - 2.43 |
| Low: | 2.23 - 2.25 | 2.25 - 2.26 |
| Close: | 2.26 - 2.28 | 2.28 - 2.3 |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Tue, 16 Jul 2024
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Down 7.1% in June - Defense World
Mon, 15 Jul 2024
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference - StockTitan
Wed, 15 May 2024
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call Transcript - Seeking Alpha
Thu, 21 Mar 2024
Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIV - Newsfile
Mon, 18 Mar 2024
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 16 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 15.1 (%) |
| Held by Institutions | 12.5 (%) |
| Shares Short | 614 (K) |
| Shares Short P.Month | 688 (K) |
| EPS | -1.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.37 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -121.7 % |
| Return on Equity (ttm) | -283.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -1.94 |
| PEG Ratio | 0 |
| Price to Book value | 6 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|